16865 results for "sec+and+unspecified+malignant+neoplasm"

in 21.20 milliseconds.

• PIAMA nasal RNAseq dataset

  This study included nasal gene expression data collected from nasal brushes of adolescents in PIAMA birth cohort, which is used in the project Nasal DNA methylation at three CpG sites predicts childhood allergic disease. 186 samples were included in this analysis, and phenotypes (age and sex) were provided together with a gene expression count table. Gene expression was measured by the Illumina HiSeq2500 sequencer.

  Dataset EGAD00001008767

• Transcriptome profiling of human lung fibroblasts in COPD

  Primary lung fibroblast were isolated from well-matched control donors (no COPD, n=3) and patients with COPD (GOLD stage I-IV, n=8). Total RNA of cultured human lung fibroblast were isolated at passage 3 and rRNA was depleted. 75 bp single-end reads were generated from RNA libraries on Illumina NextSeq 500.

  Dataset EGAD00001009405

• ATAC-Seq of GM adipose tissue samples

  This dataset contains 28 fastq files (11 files for subcutaneous tissue and 17 files for visceral tissue) from nine individuals. All samples were initially sequenced by SEx50 mode (16 files) and some of them were also sequenced by PEx100 mode (12 files). Sequencing was done on the Illumina HiSeq2000 platform.

  Dataset EGAD00001010254

• Chromatin accessibility (ATAC-seq) of human acute leukemias and healthy donors

  ATAC-seq of 79 primary samples obtained from human acute leukemias, namely AML, T-ALL and mixed myeloid/lymphoid leukemias with CpG Island Methylator Phenotype (CIMP). ATAC-seq of CD34+ HSPCs from 3 healthy donors is also included.

  Dataset EGAD00001011050

• H3K27ac ChIP-seq of human acute leukemias and healthy donors

  H3K27ac ChIP-seq of 79 primary samples derived from human acute leukemias, namely AML, T-ALL and mixed myeloid/lymphoid leukemias with CpG Island Methylator Phenotype (CIMP). In addition, 4 samples derived from CD34+ cord blood cells of healthy donors were included.

  Dataset EGAD00001011060

• 47 urothelial cancer patients WES and 38 RNAseq

  We performed a global mutational landscape analysis using tumor samples from the 47 urothelial cancer patients included in MATCH-R or MOSCATO studies, with advanced metastatic disease and WES available (RNAseq is included for 38 patient samples).

  Dataset EGAD00001011063

• Exome sequencing data from two small cell prostate cancer patients

  Exome sequencing data from two small cell prostate cancer patients - 4 cancer samples (FFPE) from Patient 1 collected at 3 different time points and 2 cancer samples (FFPE) from Patient 2 collected at 1 time point. Exonic DNA was enriched using the TruSeq Exome Kit (Illumina) and sequenced on the Illumina NextSeq 500 as 75bp paired end reads (total read length 150bp).

  Dataset EGAD00001011149

• Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole genome sequencing with histopathological features

  We performed whole genome sequencing on 42 prostate cancer samples from the prostate, seminal vesicles and regional lymph nodes of five treatment-naive patients with locally advanced disease who underwent radical prostatectomy. Whole genome sequencing was performed as 150bp paired end reads on the Illumina NovaSeq 6000 platform.

  Dataset EGAD00001011174

• WES in pleural mesothelioma primary cell lines

  We performed exome sequencing on the largest cohort of patient-derived pleural mesothelioma (PM) cell lines (n=58) to explore their molecular heterogeneity. The analysis recapitulated key features of PM tumors and uncovered novel mutations specific to this cohort. These findings provide insight into the genetic landscape of PM, supporting the identification of potential therapeutic targets and advancing the understanding of its molecular diversity.

  Dataset EGAD00001015409

• FASTQ files of the cell-free RNA from the maternal blood

  cell-free RNA from the maternal plasma obtained at round the 12, 20, 28 and 36 week gestational age from the cases of preeclampsia combined with fetal growth restriction (n=39) and their matched controls (n=156). All samples are from the Pregnancy Outcome Prediction (POP) study.

  Dataset EGAD00001015416